MX2022005407A - Treating liver disorders. - Google Patents
Treating liver disorders.Info
- Publication number
- MX2022005407A MX2022005407A MX2022005407A MX2022005407A MX2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A
- Authority
- MX
- Mexico
- Prior art keywords
- treating liver
- liver disorders
- disorders
- treating
- manifestations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962933277P | 2019-11-08 | 2019-11-08 | |
US202063004403P | 2020-04-02 | 2020-04-02 | |
PCT/US2020/059522 WO2021092474A1 (en) | 2019-11-08 | 2020-11-06 | Treating liver disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005407A true MX2022005407A (en) | 2022-05-24 |
Family
ID=75849579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005407A MX2022005407A (en) | 2019-11-08 | 2020-11-06 | Treating liver disorders. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4054567A4 (en) |
JP (1) | JP2023501386A (en) |
KR (1) | KR20220098168A (en) |
CN (1) | CN114667142A (en) |
AU (1) | AU2020380968A1 (en) |
BR (1) | BR112022008639A2 (en) |
CA (1) | CA3160445A1 (en) |
CL (1) | CL2022001167A1 (en) |
IL (1) | IL292459A (en) |
MX (1) | MX2022005407A (en) |
WO (1) | WO2021092474A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230119130A (en) | 2020-12-14 | 2023-08-16 | 리제너론 파마슈티칼스 인코포레이티드 | Methods of Treating Metabolic Disorders and Cardiovascular Disease with Inhibin Subunit Beta E (INHBE) Inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
US20140187633A1 (en) * | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
CN109152840A (en) * | 2016-03-28 | 2019-01-04 | 英特塞普特医药品公司 | Pass through the drug for combining FXR agonist and ARB to obtain |
WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
WO2019023245A1 (en) * | 2017-07-25 | 2019-01-31 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
CA3110256A1 (en) * | 2018-08-30 | 2020-03-05 | Terns Pharmaceuticals, Inc. | Treating liver disorders |
-
2020
- 2020-11-06 CN CN202080077929.8A patent/CN114667142A/en active Pending
- 2020-11-06 IL IL292459A patent/IL292459A/en unknown
- 2020-11-06 KR KR1020227018657A patent/KR20220098168A/en unknown
- 2020-11-06 EP EP20886094.0A patent/EP4054567A4/en active Pending
- 2020-11-06 JP JP2022526136A patent/JP2023501386A/en active Pending
- 2020-11-06 AU AU2020380968A patent/AU2020380968A1/en active Pending
- 2020-11-06 WO PCT/US2020/059522 patent/WO2021092474A1/en unknown
- 2020-11-06 MX MX2022005407A patent/MX2022005407A/en unknown
- 2020-11-06 BR BR112022008639A patent/BR112022008639A2/en not_active Application Discontinuation
- 2020-11-06 CA CA3160445A patent/CA3160445A1/en active Pending
-
2022
- 2022-05-04 CL CL2022001167A patent/CL2022001167A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3160445A1 (en) | 2021-05-14 |
EP4054567A1 (en) | 2022-09-14 |
CN114667142A (en) | 2022-06-24 |
JP2023501386A (en) | 2023-01-18 |
AU2020380968A1 (en) | 2022-05-12 |
WO2021092474A1 (en) | 2021-05-14 |
KR20220098168A (en) | 2022-07-11 |
IL292459A (en) | 2022-06-01 |
BR112022008639A2 (en) | 2022-07-19 |
EP4054567A4 (en) | 2024-01-10 |
CL2022001167A1 (en) | 2023-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002305A (en) | Treating liver disorders. | |
MX2020009856A (en) | Rimegepant for cgrp related disorders. | |
MX2008011633A (en) | Aminoquinolones as gsk-3 inhibitors. | |
MX2017001656A (en) | Bruton's tyrosine kinase inhibitor combinations and uses thereof. | |
WO2019099682A9 (en) | Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains | |
MX2009009761A (en) | Compositions and kits for treating influenza. | |
MY182454A (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
MX371017B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma. | |
MX2010000465A (en) | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders. | |
MX360045B (en) | Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor. | |
HK1162502A1 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3 | |
EP2023926A4 (en) | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders | |
BR112016018170A2 (en) | Methods To Treat Alzheimer's Disease | |
MX350046B (en) | Treatments for gastrointestinal disorders. | |
MX2016014731A (en) | Treatment of the complications of chronic liver disease with caspase inhibitors. | |
WO2019178487A3 (en) | Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae | |
MX2021003773A (en) | Pharmaceutical compositions comprising otic therapeutic agents and related methods. | |
MX2022014238A (en) | Combination treatment of liver disorders. | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
PH12021551223A1 (en) | Decarboxylase inhibitors for treating parkinson`s disease | |
TW200716561A (en) | P38 inhibitors and methods of use thereof | |
IL288953A (en) | Pharmaceutical compositions, kits and methods for treating tumors | |
MX2022005407A (en) | Treating liver disorders. | |
MX2022005250A (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies. | |
JOP20190164B1 (en) | Compositions and methods for treating farber disease |